Want to see AKTX full AI Analyst Report?
AKTX Stock Chart & Stats
$0.28
-$0.09(-6.73%)
At close: 4:00 PM EST
$0.28
-$0.09(-6.73%)
Day’s Range― - ―
52-Week Range$3.02 - $49.60
Previous CloseN/A
Volume16.29K
Average Volume (3M)1.63M
Market Cap
$12.60M
Enterprise Value$5.55
Total Cash (Recent Filing)$2.77M
Total Debt (Recent Filing)$732.00K
Price to Earnings (P/E)―
Beta1.46
Next Earnings
May 20, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1448.00
Shares Outstanding1,144,588
10 Day Avg. Volume2,851,768
30 Day Avg. Volume1,628,756
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio-0.02
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$27.00Price Target Upside9542.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-5.77
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageAkari’s very low reported TTM debt (~$0.7M) and minimal debt-to-equity (~0.05) materially reduce near-term solvency and interest-burden risk. For a clinical-stage biotech this conservatism preserves flexibility to prioritize R&D and licensing deals without immediate refinancing pressure.
Successful Recent Equity FinancingThe May 2026 private placement that targeted roughly $5.5M (and subsequent streamlined closings) demonstrates the company’s ability to secure near-term liquidity from investors. This structural access to capital provides runway to advance clinical programs and de-risks immediate funding gaps.
Focused Scientific NicheAkari’s strategic focus on complement-system modulation for autoimmune and inflammatory diseases creates a clear scientific specialization. This targeted expertise can produce high-value, differentiated assets and enduring competitive advantages if clinical validation and regulatory progress materialize.
Bears Say
Zero RevenuesAkari reports no product revenue across reported periods, reflecting a fully pre-commercial profile. Persistent lack of top-line inflows forces reliance on external funding to sustain R&D and operations, raising execution risk until clinical success or partnerships generate durable revenue.
Ongoing Negative Cash FlowConsistent negative operating and free cash flows (TTM FCF ≈ -$10.9M) indicate continued cash burn. Even with some improvement versus prior years, sustained negative cash generation heightens financing needs, constrains program pacing, and increases the probability of dilutive capital raises.
Dependence On Dilutive FinancingsThe company’s recent private placements, bundled warrants, and shareholder approval of broad allotment authority (through 2031) plus a waiver of pre-emption rights signal structural reliance on equity markets. That repeated, planned dilution poses long-term value erosion risk for existing shareholders.
Akari Therapeutics News
AKTX FAQ
What was Akari Therapeutics’s price range in the past 12 months?
Akari Therapeutics lowest stock price was $3.02 and its highest was $49.60 in the past 12 months.
What is Akari Therapeutics’s market cap?
Akari Therapeutics’s market cap is $12.60M.
When is Akari Therapeutics’s upcoming earnings report date?
Akari Therapeutics’s upcoming earnings report date is May 20, 2027 which is in 303 days.
How were Akari Therapeutics’s earnings last quarter?
Currently, no data Available
Is Akari Therapeutics overvalued?
According to Wall Street analysts Akari Therapeutics’s price is currently Undervalued.
Does Akari Therapeutics pay dividends?
Akari Therapeutics does not currently pay dividends.
What is Akari Therapeutics’s EPS estimate?
Akari Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Akari Therapeutics have?
Akari Therapeutics has 1,144,588 shares outstanding.
What happened to Akari Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Akari Therapeutics?
Currently, no hedge funds are holding shares in AKTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Akari Therapeutics
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.
AKTX Stock 12 Month Forecast
Average Price Target
$27.00
▲(9542.86% Upside)
Technical Analysis
Ownership Overview
25.66% Insiders
7.32% Other Institutional Investors
67.02% Public Companies and
Individual Investors